Patients with type 2 diabetes who use GLP-1 receptor agonists have a significantly lower risk for lung cancer than those who ...

CureGene Pharmaceuticals ("CureGene") today announced the first disclosure of groundbreaking preclinical data for CG-0416, a ...

WASHINGTON -- Treatment with the investigational GLP-1/glucagon dual receptor agonist pemvidutide led to resolution of ...

CVOT, notable for comparing the two drugs, tirzepatide showed significantly greater improvements in major kidney outcomes vs dulaglutide.

A multicenter team including Endeavor Health and Eli Lilly found that once-weekly eloralintide produced dose-dependent weight ...

This third of five exclusive episodes explores how clinicians can navigate newly approved MASH therapies -- resmetirom (Rezdiffra) and semaglutide (Wegovy) -- and how to tailor treatment choices based ...

"By combining precise tumour targeting with an immunotherapy payload, Daiichi Sankyo is exploring a new way to harness the ...

Administered once weekly via subcutaneous injection, semaglutide offers efficacy and durability advantages across multiple ...

The Phase I placebo-controlled, randomised, double-blind study aims to assess the safety and tolerability of MNA-001 in ...

Shares of Amgen are up nearly 26% this year and have soared 11% just over the past week.

In a small, short duration trial (12 weeks), a new medication called DR10624 reduced triglyceride levels in most patients with severe hypertriglyceridemia by more than 60%, according to a preliminary ...

The bidding war between Pfizer ( PFE) and Novo Nordisk ( NVO) over obesity drug developer Metsera ( MTSR) finally ended over ...